Rahul Kumar

AZO Stock Gets A Target Reduction From JPMorgan – But Analyst Believes It’s Good Time To Add To Positions At Current Levels

by

JPMorgan sees AutoZone’s valuation as attractive at current levels as estimates are being “right-sized,” according to a note cited by The Fly. JPMorgan attributed AutoZone’s recent 15% decline to lower same-store-sales estimates and tougher inflation comparisons ahead, according to TheFly. Truist and Raymond James also lowered their price targets following the results, while maintaining ‘Buy’ … Read more

This Quantum Computing Stock Has Gained For Six Straight Sessions, With A Buy Call From BofA

by

Bank of America has issued a buy rating for quantum computing firm IonQ, pointing to strategic corporate acquisitions and a multi-sector expansion as key drivers for long-term growth. Bank of America initiated coverage of IonQ with a ‘buy’ rating and a $60 target price, a 32% upside from last week’s closing price.  Recent buyouts of … Read more

Viral Video: Man Narrowly Escapes Falling Tree After Kicking Rocks Down Mountain! (WATCH)

by

A man’s dangerous mountain stunt nearly backfired after he kicked rocks down a slope. Moments later, a tree came crashing towards him, forcing him to move quickly to avoid falling into a nearby ravine. The incident was caught on camera. A man’s dangerous stunt on a mountain nearly ended in tragedy after he was caught … Read more

Cantor Backs Rocket Lab’s Launch Momentum After 97th Electron Mission – Highlights These ‘Competitive Advantages’

by

Cantor Fitzgerald said Rocket Lab’s launch record is a key differentiator, while reiterating an ‘Overweight’ rating and $122 price target. Cantor highlighted Rocket Lab’s mix of commercial and government customers and dedicated launch sites as ‘material competitive advantages’ Rocket Lab completed its 97th Electron mission last Saturday. Cantor identified two major upcoming catalysts, the first … Read more

OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs

by

OCUL’s selloff on Monday was spurred by clinical updates from competitors on their wet AMD treatments. Kodiak said its late-stage DAYBREAK study met its main goals: two candidates, including Zenkuda, matched Regeneron’s Eylea on vision after one year. 4D Molecular Therapeutics separately said the first patients had entered 4SIGHT, a late-stage trial of its one-time … Read more

RCL Stock In Focus — Wall Street Turns Bullish On Cruise Line Operator As Travel Demand Stays Strong

by

Bank of America and Deutsche Bank both upgraded Royal Caribbean to ‘Buy,’ citing resilient travel demand and a more attractive risk-reward after the stock’s sharp pullback in August. BoFA upgraded Royal Caribbean to ‘Buy,’ saying the recent selloff looks overdone. Deutsche Bank also upgraded the stock, pointing to a more attractive entry point after the … Read more

Know your genes: Dr Trehan on how to identify heart disease risk

by

Dr. Naresh Trehan advises individuals with a family history of heart disease to get a preventive checkup before age 25. He explains how genetic risk doubles the chances and discusses symptoms like exertional angina and emergency medication. Heart diseases have become a great concern since cases of youngsters having heart attacks started being reported. Dr … Read more

KTR promises to return ‘pattas’ to farmers losing land for Bullet Train

by

BRS’s KTR met farmers losing land for the Bullet Train project, vowing to return their titles. He also visited drought-hit farmers and demanded CM Revanth Reddy provide proof for land-grabbing allegations in Sircilla. BRS working president KTR Rama Rao on Monday met with farmers who are allegedly losing land for the Bullet Train Project in … Read more